Angioimmunoblastic T-cell Lymphoma (AITL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Angioimmunoblastic T-cell Lymphoma (AITL) is a subtype of Peripheral T-cell Lymphoma (PTCL) arising from T-follicular helper cells. It is characterized by systemic symptoms such as generalized lymphadenopathy, hepatosplenomegaly, anemia, and hypergammaglobulinemia, with a median age of onset at around 60 years of age and no gender preference. More than 80% of patients with AITL present with advanced stage (III/IV) disease at the time of diagnosis, often accompanied by constitutional symptoms such as fever, chills, and weight loss. Mutations in epigenetic regulators TET2, DNMT3A, and IDH2 have been found in PTCL and are more frequent in AITL and T-cell lymphomas with a follicular helper T-cell phenotype. The presence of these mutations is linked to the RHOA G17V mutation, supporting a multistep model of T-cell transformation in AITL. The differential diagnosis for AITL includes reactive lymphoid hyperplasia, Hodgkin's disease, T-cell-rich large B-cell lymphoma, and other types of PTCL. There is currently no standard therapy for AITL, and various regimens, either as single agents or combinations, have been used for treatment. Anthracycline-based therapy is considered the first line of treatment. The prognosis for patients with AITL is poor, with a median survival of less than 3 years.
·
The incidence of AILT is low, with only 0.05
new cases per 100,000 individuals in the USA.
Thelansis’s “Angioimmunoblastic T-cell
Lymphoma (AITL) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Angioimmunoblastic
T-cell Lymphoma (AITL) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Angioimmunoblastic T-cell Lymphoma (AITL) across 8 MM market from the centre
of Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Angioimmunoblastic T-cell Lymphoma
(AITL) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech business
environment to provide an optimized support system to all levels of the
decision-making process. It enables business leaders in forward-thinking and
proactive decision-making. Thelansis supports scientific and commercial teams
in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment